Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) has earned an average recommendation of “Buy” from the twenty-two analysts that are covering the stock, Analyst Ratings Network reports. Five equities research analysts have rated the stock with a hold recommendation and fifteen have issued a buy recommendation on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $345.94.

REGN has been the subject of a number of recent research reports. Analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. Finally, analysts at Deutsche Bank raised their price target on shares of Regeneron Pharmaceuticals from $410.00 to $425.00 in a research note on Tuesday, August 5th. They now have a “buy” rating on the stock.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $347.65, for a total transaction of $695,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 348.62 on Tuesday. Regeneron Pharmaceuticals has a 52-week low of $227.64 and a 52-week high of $352.49. The stock has a 50-day moving average of $316. and a 200-day moving average of $308.5. The company has a market cap of $34.998 billion and a P/E ratio of 98.96.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, August 5th. The company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter in the previous year, the company posted $1.73 earnings per share. The company’s revenue for the quarter was up 45.4% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $10.14 EPS for the current fiscal year.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.